TCGA-A8-A08O-01A-21R-A056-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 31
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.450
- TGF_BETA_SIGNALING+0.420
- PROTEIN_SECRETION+0.410
- ESTROGEN_RESPONSE_EARLY+0.360
- MITOTIC_SPINDLE+0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- APICAL_SURFACE+0.230
- ESTROGEN_RESPONSE_LATE+0.170
- ANGIOGENESIS+0.140
- NOTCH_SIGNALING+0.140
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.550
- INTERFERON_ALPHA_RESPONSE-0.550
- INTERFERON_GAMMA_RESPONSE-0.540
- IL6_JAK_STAT3_SIGNALING-0.460
- INFLAMMATORY_RESPONSE-0.440
- TNFA_SIGNALING_VIA_NFKB-0.410
- KRAS_SIGNALING_UP-0.330
- COMPLEMENT-0.300
- IL2_STAT5_SIGNALING-0.290
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AR-A1AV-01A-21R-A12P-07 | — | B | 0.840 |
| 2 | TCGA-B6-A0WT-01A-11R-A109-07 | — | B | 0.836 |
| 3 | TCGA-D8-A1XD-01A-11R-A14D-07 | — | B | 0.834 |
| 4 | TCGA-A1-A0SE-01A-11R-A084-07 | — | A | 0.819 |
| 5 | TCGA-CR-7372-01A-11R-2016-07 | — | — | 0.811 |
| 6 | TCGA-AN-A0FZ-01A-11R-A034-07 | — | B | 0.804 |
| 7 | SRR8518326 | — | E | 0.803 |
| 8 | TCGA-BH-A0E7-01A-11R-A034-07 | — | B | 0.790 |
| 9 | SRR25617938 | — | B | 0.781 |
| 10 | TCGA-K4-A6MB-01A-11R-A31N-07 | — | — | 0.779 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.450 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.420 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.360 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.310 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.140 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.140 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.130 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.120 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.090 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.050 | Inavolisib | — uncovered |
| MYOGENESIS | 0.020 | Inavolisib | — uncovered |